Clinical trials: Neoadjuvant
NSCLC Stage IIIB, NSCLC Stage IIIC
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were…
- Trial name
- NCT06829641
- Testing
- Tislelizumab Combined with Chemotherapy,
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Hemophagocytic Syndrome
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
Adult secondary HLH involves tumors, autoimmune diseases and other causes in addition to infection,Infectious factors, theoretically need different treatment methods for different etiology.
- Trial name
- NCT05936086
- Testing
- Cytoxan, Etoposide, Dexamethasone
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- shifeng Lou
Melanoma
Neoadjuvant T-VEC in High Risk Early Melanoma
Despite the recent notable advances in the treatment of advanced melanoma with application of growing immunotherapies, patterns of response and factors resulting in treatment failure are poorly understood.
- Trial name
- NCT04427306
- Testing
- T-Vec
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Urothelial Carcinoma
The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer
Recently, promising evidences that blocking PD-1 and PD-L1 is an efficacious way to treat advanced stage bladder cancer patients. Atezolimumab is the first PD-L1 inhibitor approved by US FDA for advanced UBC in June 2014.
- Trial name
- NCT03577132
- Testing
- Neoadjuvant atezolizumab
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Breast Cancer
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
The aim of this study is to explore the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients (ypN+or supra/subclavicular lymph node positive) after neoadjuvant chemotherapy.
- Trial name
- NCT06559696
- Testing
- internal mammary nodal irradiation, No internal mammary node irradiation
- Where
- China
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Breast Cancer
Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study
In this study the characteristics and alterations of the gut microbiome during neoadjuvant therapy for HER2-positive breast cancer patients are studied, as well as the relation between the gut microbiome and probability of pCR.
- Trial name
- NCT05444647
- Testing
- stool and blood collection
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）
This trial is a multi-center, open, single-arm, superior phase II clinical study.
- Trial name
- NCT05113459
- Testing
- Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guoxin Li
Breast Neoplasms
A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
This is a pilot study evaluating the use of tumor derived exosomes as a marker for response to therapy in women receiving neoadjuvant chemotherapy for newly diagnosed breast cancer.
- Trial name
- NCT01344109
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Leo W. Jenkins Cancer Center
Breast Cancer, Breast Diseases
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
This study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms
- Trial name
- PECP (NCT03756090)
- Testing
- Palbociclib, Epirubicin, Cyclophosphamide
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Female
Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients
This is a phase II randomized trial comparing pathologic complete response rates in locally advanced patients recieving either neoadjuvant chemotherapy or neoadjuvant chemoradiation.
- Trial name
- NCT06631066
- Testing
- neoadjuvant chemoradiation
- Where
- Egypt
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute, Egypt
Neoadjuvant Chemoradiotherapy, Rectal Tumor
Outcomes of Resection at Different Times Between the End of Neoadjuvant Treatment and Surgery
Neoadjuvant radio-chemotherapy (NRCT) represents a milestone in the treatment of selected rectal tumours. Ideal time interval between the end of NRCT and surgery is still debated; a 6-8 weeks time interval is considered optimal…
- Conditions
- Neoadjuvant Chemoradiotherapy, Rectal Tumor, Surgery, Surgery--Complications
- Trial name
- NCT04013347
- Testing
- Rectal Resection
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Campus Bio-Medico University
Rectal Cancer
Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
The aim of this study is to evaluate the efficacy and safety of additional neoadjuvant chemotherapy with capecitabine during the resting periods in patients with locally advanced rectal cancer.
- Trial name
- NCT01671683
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chungnam National University
T-Cell Dysfunction, Chemotherapy Effect
Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC
The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer…
- Conditions
- T-Cell Dysfunction, Chemotherapy Effect, Adverse Events
- Trial name
- STFREiYTNBC (NCT06684054)
- Testing
- docetaxel, anthracycline, cyclophosphamide
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Rectal Cancer
A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer
Background: Neoadjuvant chemoradiotherapy (CRT) and total mesorectum excision (TME) has become the standard therapy for the treatment of locally advanced rectal cancer (LARC) to reduce the local recurrence rate, however, no…
- Trial name
- NCT03245203
- Testing
- FOLFIRI+beacizumab, CRT
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Locally Advanced Cervical Carcinoma
How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix
1. This strategy might suggest a therapeutic option to preserve ovarian function in young patients among which locally advanced cancer cervix is common.
- Trial name
- NCT04789941
- Testing
- Cis Platinum + Irinotecan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Esophageal Cancer
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer
The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced resectable…
- Trial name
- NCT05547529
- Testing
- Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy., Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
- Where
- Russia
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Non-Small Cell Lung Cancer
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world.
- Trial name
- NeoR-World (NCT05974007)
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sentinel Lymph Node Biopsy, Neoadjuvant Therapy
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer…
- Conditions
- Sentinel Lymph Node Biopsy, Neoadjuvant Therapy, Breast Neoplasm
- Trial name
- NCT06212440
- Testing
- Radioactive Isotope (RI) Mapping, Indocyanine Green Fluorescence (ICG-F) Mapping, Vital Dye Mapping
- Where
- 2 sites in South Korea
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Breast Cancer
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare…
- Trial name
- NCT06268327
- Testing
- Cisplatin injection and gemcitabine, Capecitabine tablets
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype.
- Trial name
- NCT02978495
- Testing
- Doxorubicin, Carboplatin, Paclitaxel
- Where
- Brazil
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Barretos Cancer Hospital